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Objectives. The transposed basilic vein to brachial artery arteriovenous fistula provides secondary vascular access for
haemodialysis. The long-term results of such fistula are assessed in this retrospective series.
Material and methods. Over a 5-year period 75 brachiobasilic transposition fistulae were performed in 74 patients. There
was a median follow up of 14 months.
Results. Primary patency was achieved in 69 (92%) of the fistulae, and secondary patency in 74 (99%) of the fistulae.
Successful interventions included angioplasties in four, and saphenous vein interposition in one, whilst three patients had
failed thrombectomies. Dialysis was performed using 69 (92%) of the fistulae while 6 (8%) were never used. Of the 75
fistulae 47 (63%) were patent at follow up. Cumulative secondary patency was 66% at 1 year, 52% at 2 years, and 43% at 3
years. Complications developed in 41 (55%), and included thrombosis, infection, stenosis, arm oedema, bleeding, steal
syndrome and microaneurysm formation.
Conclusions. Brachiobasilic transposition fistulae have good long-term patency rates. The complication rate, although high,
is lower than that reported for PTFE grafts. Brachiobasilic fistulae should be used in preference to PTFE grafts for secondary
access.
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Introduction
The ideal vascular access for haemodialysis is either a
radiocephalic fistula or a brachiocephalic fistula.
However, in those patients in whom these fail, or in
whom the cephalic vein is not available, another
solution is sought. A frequently used option is to use a
graft such as polytetrafluoroethylene (PTFE). How-
ever, these are associated with a substantial compli-
cation rate.1,2
The alternative to a PTFE graft is to transpose the
basilic vein through a subcutaneous tunnel to an
anterior position in the upper arm, where it is
accessible for cannulation. The vein is then anasta-
mosed end-to-side to the brachial artery in the
antecubital fossa.3 Because of the position of the basilic
vein deep to the fascia it has rarely suffered veno-
puncture or cannulation and with its large calibre,
usually proves a satisfactory conduit.
In this study of patients who had undergone
brachiobasilic transposition fistula long term patency
rates and complications were examined. In addition
the effect of concurrent disease on patency was also
evaluated.
Material and Methods
Brachiobasilic transposition fistulae were created for
patients in end stage renal failure in whom haemo-
dialysis was being considered. These were either
patients in whom previous vascular access had failed,
or in whom alternative vascular access such as
radiocephalic or brachiocephalic fistula were not
possible. Patients who had previously had central
vein cannulation for haemodialysis access on the same
side as the proposed fistula underwent preoperative
imaging to exclude central venous stenosis.
Brachiobasilic fistulae were created using a tech-
nique similar to that described by Dagher et al.3 A
transverse incision across the antecubital fossa was
made and then extended longitudinally up the medial
aspect of the upper arm to expose the basilic vein,
lying adjacent to the brachial artery. Care was taken to
avoid damage to the medial cutaneous nerve of the
arm. The vein was dissected out and its tributaries tied
using 3-0 polyglactin. The vein was then tied and
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divided distally at the level of the elbow. The free end
of the vein was then tunnelled in a subcutaneous
position down the anterior aspect of the upper arm. In
the antecubital fossa it was anastamosed end-to-side
with the brachial artery using 6-0 polyproplyene. The
subcutaneous tissues and skin were closed with an
absorbable suture. The fistula was then used for
dialysis after an interval of 6 weeks.
Patient notes were examined retrospectively. Dur-
ation of follow-up and patency were recorded. Patency
was assessed either by palpation for a thrill, ausculta-
tion for a bruit, or by using a Doppler probe. Primary
patency was said to be achieved if there was
satisfactory flow in the fistula at 6 weeks without
further intervention. The fistula was considered to
have developed secondary patency if another invasive
procedure, such as angioplasty or thrombectomy, was
required. Cumulative secondary patency rates
included both those who developed primary and
secondary patency.
In addition, a note was made of the presence of
factors such as gender, hypertension, cardiovascular
disease, diabetes mellitus, smoking, previous vascular
access, and the use of medication such as aspirin,
warfarin or erythropoietin. These factors were com-
pared between the group that had remained patent,
and the group that occluded.
The Mann–Whitney test was used to compare age
and number of previous access attempts, t-test was
used to compare haemoglobin and albumin, and chi-
square tests were used for the remaining variables.
Because repeated comparisons were made, a Bonfer-
roni correction was applied to the p value calculated. A
p value of 0.004 (i.e. 0.05/12) was required to be
considered significant.
Results
Seventy-five brachiobasilic transposition fistulae were
created in 74 patients, median age 49 years (range 6–
77 years). There was a median follow-up of 14 months
(range 8 days (no patency)—54 months).
Primary patency was achieved in 69 (92%) of the
fistulae, and a cumulative secondary patency in 74
(99%) of the fistulae. Of those who developed
secondary patency, four underwent successful angio-
plasties, and one required a saphenous vein interposi-
tion as a secondary procedure. Unsuccessful
secondary procedures were exploration and throm-
bectomy in three patients, in whom patency was not
achieved.
Haemodialysis was performed through 69 (92%) of
the brachiobasilic transposition fistulae. Of the 75
fistulae, 47 (63%) were patent at follow-up, including
36 (48%) that are still in use. Seven patients died with
functioning fistulae, four received renal transplants,
and one was not needled. Fig. 1 shows a graph of the
change of cumulative secondary patency with time.
Cumulative secondary patency was 66% at 1 year, 52%
at 2 years, and 43% at 3 years.
A comparison between the group of patients whose
fistula remained patent, and those in whom the fistula
occluded are shown in Table 1. No statistically
significant differences were found between the two
groups.
Complications occurred in 41 (55%) of the patients,
with some patients having more than one compli-
cation. These included thrombosis of the fistula in 25
(33%), stenosis in eight (11%), arm oedema in three
(5%), bleeding from two (3%), and steal syndrome in
one (1%). Local infection occurred in six (8%),
necessitating ligation of the fistula in two. One patient
(1%) had microaneurysm formation that also required
ligation of the fistula.
Discussion
With increasing numbers of patients requiring hae-
modialysis, there is a growing problem of how
vascular access should be achieved in patients in
whom radiocephalic fistula or a brachiocephalic fistula
cannot be fashioned. This series is one of the largest
to provide long-term follow-up information on
patients who have undergone brachiobasilic vein
transposition.
Good primary and secondary patency rates have
been demonstrated. The results of this study are
comparable to those of others previously published,
where patency rates of 68–87% have been quoted.3 – 7
Fig. 1. Cumulative secondary patency of brachiobasilic
transposition fistula.
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In the longer term functional patency of 70% at 8
years8 has been demonstrated. The National Kidney
Foundation DOQI guidelines recommend that patency
rates of 70% at 1 year, 60% at 2 years, and 50% at 3
years should be achievable with all kinds of arter-
iovenous fistula.9 In our study, this level is practically
achieved at year one, but not met at years two and
three. However, our patency matches those of other
comparably large series,6,7 suggesting perhaps that the
DOQI targets may be over ambitious for this particular
kind of fistula.
There is a significant complication rate in patients
who have brachiobasilic transposition fistula, with
half of the patients being affected. However, this
compares favourably with alternative secondary
access procedures, such as the use of PTFE grafts.
These have patency rates of 62–70% at 1 year,10,11 50%
at 2 years and 43% at 4 years.2 Complications that
compromise patency in these grafts include thrombo-
sis in 21%, infection in 25% and intimal hyperplasia in
34%.2 Overall complication rates of 60–95% have been
reported for PTFE grafts.1,2,12 Autologous material for
arteriovenous fistulae will have better patency and less
complications than prosthetic material.13 A direct,
though non-randomised, comparison of brachiobasilic
fistula against PTFE grafts has confirmed better
patency of the transposed fistula.14 The superiority of
the brachiobasilic fistula is given further weight by the
practice guidelines of the National Kidney Foundation
which recommend their use in preference to PTFE
grafts.9
In this retrospective study it is difficult to attribute
any role for aspirin or warfarin in protecting graft
patency. There was certainly no differences in the
proportion of those taking these medications in
the group who remained patent compared against
the group who occluded. One explanation would be
that aspirin or warfarin played no role. Another
explanation may be that patients who were at higher
risk of occlusion were correctly identified and ade-
quately protected with aspirin or warfarin. The most
sensible explanation would simply be that there were
too few numbers for any meaningful conclusion to be
drawn on this particular observation.
In summary, brachiobasilic transposition fistulae
provide useful secondary access for haemodialysis,
with good initial patency rates that persist out to 3
years. Although there is a significant complication
rate, this compares favourably with alternative
methods for secondary access. Ultimately a random-
ised controlled trial comparing transposed brachioba-
silic fistula and PTFE grafts would establish the
relative merits of these procedures.
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Table 1. Differences between the patients in whom the fistula
remained patent, and those in whom the fistula occluded.
Criteria Patent ¼ 46 Occluded ¼ 29 P
Age (median) 50.5 44.0 0.25
Female 25 (54%) 15 (52%) 0.82
Hypertension 15 (33%) 11 (38%) 0.57
Cardiovascular disease 16 (35%) 16 (55%) 0.096
Diabetes 9 (20%) 5 (17%) 0.84
Aspirin 11 (24%) 9 (31%) 0.61
Warfarin 6 (13%) 6 (21%) 0.48
Erythropoietin 32 (70%) 17 (59%) 0.12
Mean haemoglobin (g/dl) 10.2 ^ 1.6 9.4 ^ 1.6 0.092
Mean albumin (g/L) 37.2 ^ 5.9 33.5 ^ 5.7 0.029
Smoker 13 (28%) 8 (28%) 0.71
Median previous access (range) 1 (0–4) 1 (0–4) 0.82
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